Perioperative Management of Metformin
Introduction to Metformin Management
- Metformin should be suspended the night before surgery and not restarted until 48 hours after major surgery, after verifying adequate renal function, as recommended by the Anaesthesia guidelines 1
- The primary risk factor for lactic acidosis associated with metformin is renal insufficiency, with other factors including iodinated contrast media administration, dehydration, fasting, and severe heart failure 1
- Lactic acidosis is a rare but serious complication of metformin, with a mortality rate of 30-50% and an incidence of 2-9 per 100,000 patients per year 1
Patient Evaluation and Monitoring
- Renal function should be evaluated after surgery before restarting metformin due to the potential severity of lactic acidosis 1
- Renal insufficiency (creatinine clearance < 60 mL/min) and severe heart failure (ejection fraction < 30%) are significant risk factors for lactic acidosis associated with metformin 1
- Patients with multiple comorbidities (renal impairment, heart failure) require special attention due to increased risk of lactic acidosis, with careful assessment and management recommended by the American Society of Anesthesiologists and European Society of Cardiology guidelines 1, 2
Treatment and Prevention
- Metformin suspension is primarily preventive, based on the potential risk of lactic acidosis, which increases with factors that compromise renal function during the perioperative period 1
- In cases of suspected lactic acidosis, immediate hemodialysis is recommended, although this specific recommendation lacks a cited reference, the cautious approach is supported by the potential severity of lactic acidosis 1
- To reduce the risk of contrast-induced nephropathy during catheterization, administering adequate preprocedural hydration with isotonic saline (1 mL/kg/h 12 hours before and continued for 24 hours after the procedure) is recommended, as per guidelines that may be informed by the European Heart Journal 3
- Minimizing contrast media volume (<350 mL or <4 mL/kg) and using low- or iso-osmolar contrast media can reduce the risk of AKI, aligning with practices suggested by the European Heart Journal 3
- Using radial artery access when feasible and administering high-intensity statins before the procedure can also reduce the risk of AKI, as suggested by research that may be published in the Journal of the American College of Cardiology and the American College of Cardiology 4
Management of Metformin in Cardiac Catheterization
- For patients with normal renal function, metformin should not be routinely stopped before cardiac catheterization, but rather withheld for 48 hours after the procedure only if renal function deteriorates, as recommended by the European Society of Cardiology 2
- For patients with pre-existing renal impairment, metformin should be stopped 48 hours before the procedure, with the American Society of Anesthesiologists and European Society of Cardiology guidelines emphasizing the importance of renal function assessment 2, 1
- The following table summarizes the management of metformin in patients undergoing cardiac catheterization:
| Renal Function | Pre-Procedure | Post-Procedure |
|---|---|---|
| Normal | No stoppage | Withhold for 48 hours if renal function deteriorates |
| Impaired | Stop 48 hours before | Withhold until renal function stabilizes |
- Monitoring renal function after the procedure is crucial, especially for patients on certain medications, to promptly identify any deterioration in renal function, as might be suggested by the European Society of Cardiology, though not directly cited here 4
- Re-evaluating renal function (eGFR) after the contrast procedure is a critical step in medication management, with the principle of monitoring renal function post-procedure supported by the European Society of Cardiology guidelines 2